Jump to content
RemedySpot.com

NEJM Article

Rate this topic


Guest guest

Recommended Posts

Are we really surprised??? I loved the

silence from and Dr. K when Larry King asked them about Autism Speaks. I

hope they feel about two inches tall.

Pamela

" Courage is doing

what you're afraid to do. There can be no courage unless you're scared. "

Eddie Rickenbacker,

top US

fighter ace, WWI

From:

EOHarm [mailto:EOHarm ] On Behalf Of pamelacares

Sent: Thursday, September 27, 2007

10:40 AM

EOHarm

Subject: NEJM article

Autism Speaks - fair and balanced again. New England

Journal article

up, McCarthy off the home page!!

Link to comment
Share on other sites

I loved the way she blurted out, "I am with TACA." Then Holly stammers a little and mentions that she has met Suzanne and but that is all she would say.I hope this speaks volumes to a lot of parents who do these walks.RoxPamela Leigh <pamelaleigh@...> wrote: Are we really surprised??? I loved the silence from and Dr. K when Larry King asked

them about Autism Speaks. I hope they feel about two inches tall. Pamela "Courage is doing what you're afraid to do. There can be no courage unless you're scared." Eddie Rickenbacker, top US fighter ace, WWI From: EOHarm [mailto:EOHarm ] On Behalf Of pamelacares Sent: Thursday, September 27, 2007 10:40 AM EOHarm Subject: NEJM

article Autism Speaks - fair and balanced again. New England Journal article up, McCarthy off the home page!!

Pinpoint customers who are looking for what you sell.

Link to comment
Share on other sites

  • 9 months later...
Guest guest

Why Doctors Should Worry about Preemption

http://content.nejm.org/cgi/content/full/359/1/1?query=TOC

Quote:

Although frivolous lawsuits should not be

condoned, product-liability litigation has unquestionably helped to

remove unsafe products from the market and to prevent others from

entering it. Through the process of legal discovery, litigation may

also uncover information about drug toxicity that would otherwise

not be known. Preemption will thus result in drugs and devices that

are less safe and will thereby undermine a national effort to improve

patient safety.

Owing

in part to a lack of resources, approval of a new drug by the FDA is

not a guarantee of its safety (see timeline).4

As the Institute

of Medicine has reported,

FDA approval is usually based on short-term efficacy studies, not

long-term safety studies.5

Despite the diligent attention of the FDA, serious safety issues often

come to light only after a drug has entered the market. The FDA,

which — unlike most other federal agencies — has no

subpoena power, knows only what manufacturers reveal.

s. fuchs dc

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...